Teva Pharmaceuticals

NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials

Retrieved on: 
среда, мая 29, 2024
Intellectual property, Investigational New Drug, NRX, News, Teva Pharmaceuticals, Laboratory, Exercise, FDA, Bank statement, Safety, Head, Research, Growth, Regenerative medicine, Contract research organization, Acceleration, TSX Venture Exchange, Pharmaceutical industry

On March 22, 2024, the Company completed the acceleration of 12,682,340 warrants issued pursuant to a private placement of units that closed on June 15, 2022.

Key Points: 
  • On March 22, 2024, the Company completed the acceleration of 12,682,340 warrants issued pursuant to a private placement of units that closed on June 15, 2022.
  • “We appreciate the confidence of the investors who exercise their warrants, and the ongoing support of NurExone’s journey,” stated Eran Ovadya, NurExone Chief Financial Officer.
  • Net loss was US$0.92 million in the first quarter of 2024, compared to a net loss of US$0.70 million in the first quarter of 2023.
  • Eran Ovadya, NurExone’s Chief Financial Officer, added: “The Company maintains a strong cash position, ensuring sufficient funding until year-end.

Assertio Announces the Appointment of Brendan P. O’Grady as New CEO

Retrieved on: 
среда, мая 29, 2024
Patient, State university system, Business administration, Growth, Interim, Baker University, Glenmark Pharmaceuticals, ASRT, Master of Business Administration, Teva, Teva Pharmaceuticals, Management

Most recently, Mr. O’Grady was CEO of the Global Formulations business at Glenmark Pharmaceuticals, driving new product launches and focused on growing profitability in key markets.

Key Points: 
  • Most recently, Mr. O’Grady was CEO of the Global Formulations business at Glenmark Pharmaceuticals, driving new product launches and focused on growing profitability in key markets.
  • Prior, he was Chief Commercial and Growth Officer at Amwell, building a go-to-market strategy at the digital telehealth provider.
  • Peter Staple, Chairman of the Board, said, “The Board is delighted to welcome Brendan to Assertio as our new CEO.
  • We also look forward to Heather’s continuing contributions as she transitions back to her role as an independent director.”

Asymchem Welcomes Franck Mevellec as Senior Director, Business Development

Retrieved on: 
среда, мая 29, 2024
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Growth, Peptide, Drug development, SVP, Bayer, CDMO, Teva Pharmaceuticals, Fine chemical

Asymchem , a leading global CDMO, is excited to announce the appointment of Franck Mevellec as senior director, business development.

Key Points: 
  • Asymchem , a leading global CDMO, is excited to announce the appointment of Franck Mevellec as senior director, business development.
  • Franck brings over 20 years of experience in the pharmaceutical industry, working across various aspects of drug development from R&D to sales.
  • He joins Asymchem with a focus on expanding the company’s footprint across Europe.
  • “Franck’s extensive experience and deep understanding of the European pharmaceutical market make him a valuable asset to our team,” said Jon Brice , SVP of business development at Asymchem.

Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day)

Retrieved on: 
среда, мая 29, 2024
Research, Mental Health, Neurology, FDA, Clinical Trials, Biotechnology, Managed Care, Pharmaceutical, Health, Science, Insurance, Chorea, Patient, Eating, TMC, Food, HD, Medication, TEVA, Walking, VMAT2, DSM-IV codes, Senior, Behavior, Teva, Teva Pharmaceuticals, Pharmaceutical industry

Innovative Medicines at Teva.

Key Points: 
  • Innovative Medicines at Teva.
  • “AUSTEDO, backed by the longest efficacy and tolerability data to date, has continued to evolve – having received approval for AUSTEDO XR, our once-daily extended-release formulation in February 2023.
  • Savings on out-of-pocket costs may vary depending on the patient’s insurance provider and eligibility for participation in the co-pay assistance program.
  • For more information regarding cost and coverage options for AUSTEDO XR through Teva Shared Solutions, visit MySharedSolutions.com .

Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update

Retrieved on: 
вторник, мая 21, 2024
Partnership, CTA, Patient, EBIDTA, Icelandic, Food, Movement, Clinical trial, FDA, EDT, Marketing, Ustekinumab, Food and Drug Administration, Absorption, Denosumab, Research, G&A, Biosimilar, Adalimumab, Webcast, Teva, Teva Pharmaceuticals, Generic drug

Gross margin in Q1 2024 increased to $17 million, by $40 million compared to the same period last year.

Key Points: 
  • Gross margin in Q1 2024 increased to $17 million, by $40 million compared to the same period last year.
  • Alvotech raises topline revenue guidance to $400-$500 million and tightens guidance for bottom line range for 2024 to $100-$150 million.
  • Management will conduct a business update conference call and live webcast on Wednesday May 22, 2024, at 8:00 am ET (12:00 pm GMT).
  • Alvotech will conduct a business update conference call and live webcast on Wednesday, May 22, 2024, at 8:00 am EDT (12:00 pm GMT).

Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.

Retrieved on: 
вторник, мая 21, 2024
Partnership, Patient, Uveitis, Prescription, Food, Rheumatoid arthritis, Johnson & Johnson, FDA, TEVA, Marketing, Ustekinumab, Psoriasis, Ankylosing spondylitis, Senior, Ulcerative colitis, Juvenile idiopathic arthritis, Hidradenitis suppurativa, Adalimumab, Teva, Teva Pharmaceuticals, Generic drug

“We are proud to make SIMLANDI available in the U.S. to patients and providers,” said Thomas Rainey, Senior Vice President, U.S. Market Access at Teva.

Key Points: 
  • “We are proud to make SIMLANDI available in the U.S. to patients and providers,” said Thomas Rainey, Senior Vice President, U.S. Market Access at Teva.
  • “Biosimilars create opportunities for cost savings across the healthcare system, and SIMLANDI’s launch now offers the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. market.
  • Alvotech handles development and manufacturing, while Teva is responsible for the exclusive commercialization in the U.S., which leverages Teva’s experience and extensive sales and marketing infrastructure.
  • Humira is a registered trademark of AbbVie Biotechnology Ltd. Stelara is a registered trademark of Johnson & Johnson.

NurExone Welcomes Biopharma Exec Dr. Ram Petter to Drive Strategic Collaborations

Retrieved on: 
пятница, мая 17, 2024
MBA, Regenerative medicine, NRX, OTCQB, Teva Pharmaceuticals

TORONTO and HAIFA, Israel, May 17, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, proudly welcomes Dr. Ram Petter, Ph.D., MBA, as a consultant, to assist in driving the Company’s strategic collaborations.

Key Points: 
  • TORONTO and HAIFA, Israel, May 17, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, proudly welcomes Dr. Ram Petter, Ph.D., MBA, as a consultant, to assist in driving the Company’s strategic collaborations.
  • Dr. Petter will leverage his experience to support NurExone's operational activities and facilitate the Company’s strategic engagement in the effort to fully realize NurExone's potential and maximize its reach.
  • "Our ExoTherapy platform for drug delivery is ready for industry partnerships targeting clinical indications beyond acute spinal cord injury," says Dr. Lior Shaltiel, CEO of NurExone.
  • "Ram’s extensive experience and strategic acumen will be most helpful in forging these critical collaborations."

Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.

Retrieved on: 
вторник, мая 21, 2024
Biotechnology, FDA, Pharmaceutical, Health, Partnership, Patient, Uveitis, Prescription, Food, Rheumatoid arthritis, Johnson & Johnson, Medication, TEVA, Marketing, Ustekinumab, Psoriasis, Ankylosing spondylitis, Senior, Ulcerative colitis, Juvenile idiopathic arthritis, Hidradenitis suppurativa, Adalimumab, Multimedia, Teva, Teva Pharmaceuticals

View the full release here: https://www.businesswire.com/news/home/20240520679234/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240520679234/en/
    “We are proud to make SIMLANDI available in the U.S. to patients and providers,” said Thomas Rainey, Senior Vice President, U.S. Market Access at Teva.
  • “Biosimilars create opportunities for cost savings across the healthcare system, and SIMLANDI’s launch now offers the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. market.
  • Alvotech handles development and manufacturing, while Teva is responsible for the exclusive commercialization in the U.S., which leverages Teva’s experience and extensive sales and marketing infrastructure.
  • Humira is a registered trademark of AbbVie Biotechnology Ltd.
    Stelara is a registered trademark of Johnson & Johnson.

Royalty Pharma Reports First Quarter 2024 Results

Retrieved on: 
четверг, мая 9, 2024
FDA, Ulcerative colitis, KarXT, Food, MorphoSys, European Commission, Marketing, New Drug Application, Cystic fibrosis, PDSS, PANSS, Tourette syndrome, Lupus, Docetaxel, Roche, Schizophrenia, Novartis, ADP, Pfizer, Incidence, Bristol Myers Squibb, Patient, Neurology, Acquisition, Sacituzumab govitecan, Olanzapine, Civil service commission, Multiple sclerosis, Positive, Vertex, Sanofi, Teva Pharmaceuticals, Astellas Pharma, European Medicines Agency, Lung cancer, Pharmaceutical industry

During 2024, Royalty Pharma announced new transactions of up to $619 million.

Key Points: 
  • During 2024, Royalty Pharma announced new transactions of up to $619 million.
  • In January 2024, Royalty Pharma acquired a royalty interest in ecopipam for an upfront payment of $49 million and up to $44 million in milestone payments contingent on the achievement of certain regulatory milestones.
  • In May 2024, Royalty Pharma announced a transaction to acquire royalties and milestones on frexalimab owned by ImmuNext for approximately $525 million in cash including estimated transaction costs.
  • Royalty Pharma has provided guidance for full year 2024, excluding transactions and borrowings announced after the date of this release, as follows:

Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia

Retrieved on: 
среда, мая 8, 2024
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Schizophrenia, TEVA, Positive, Medication, PANSS, Patient, Teva Pharmaceuticals, Olanzapine

Results demonstrated that TEV-‘749 met its primary endpoint as measured by a change in the PANSS total score from baseline after 8 weeks compared to placebo.

Key Points: 
  • Results demonstrated that TEV-‘749 met its primary endpoint as measured by a change in the PANSS total score from baseline after 8 weeks compared to placebo.
  • These differences from placebo were clinically meaningful and statistically significant with adjusted P-values of
  • Currently, there is no long-acting olanzapine treatment option available for schizophrenia that does not risk post-injection delirium/sedation syndrome (PDSS).
  • Schizophrenia is often a chronic life-long disease, but by using medication consistently, people can find the treatment help they deserve.